Literature DB >> 24433194

Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children.

John D Hart1, Tansy Edwards, Sarah E Burr, Emma M Harding-Esch, Kensuke Takaoka, Martin J Holland, Ansumana Sillah, David C W Mabey, Robin L Bailey.   

Abstract

OBJECTIVE: To assess the effect of azithromycin mass drug administration regimens on spleen rates in children aged 0-5 years.
METHODS: Clinical assessment of spleen size was carried out during a cluster-randomised trial of azithromycin mass treatment for trachoma elimination in The Gambia. Twenty-four communities received three annual mass treatments with azithromycin, and 24 communities received treatment at baseline only.
RESULTS: At the 30-month follow-up, 3646 children aged 0-5 years had spleen examination and measurement. Palpable splenomegaly was significantly lower in annually treated vs. baseline-only treatment communities and in treated vs. untreated children at 24 months in the annual treatment arm.
CONCLUSION: The results suggest an effect of azithromycin on spleen rates at the individual level and are most plausibly due to the antimalarial effects of azithromycin.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  azithromycin; malaria; mortality; spleen; splenomegaly

Mesh:

Substances:

Year:  2014        PMID: 24433194     DOI: 10.1111/tmi.12234

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  7 in total

1.  Antibiotics for trachoma.

Authors:  Jennifer R Evans; Anthony W Solomon; Rahul Kumar; Ángela Perez; Balendra P Singh; Rajat Mohan Srivastava; Emma Harding-Esch
Journal:  Cochrane Database Syst Rev       Date:  2019-09-26

2.  The global burden of disease study 2013: What does it mean for the NTDs?

Authors:  Jennifer R Herricks; Peter J Hotez; Valentine Wanga; Luc E Coffeng; Juanita A Haagsma; María-Gloria Basáñez; Geoffrey Buckle; Christine M Budke; Hélène Carabin; Eric M Fèvre; Thomas Fürst; Yara A Halasa; Charles H King; Michele E Murdoch; Kapa D Ramaiah; Donald S Shepard; Wilma A Stolk; Eduardo A Undurraga; Jeffrey D Stanaway; Mohsen Naghavi; Christopher J L Murray
Journal:  PLoS Negl Trop Dis       Date:  2017-08-03

3.  Effect of Mass Treatment with Azithromycin on Causes of Death in Children in Malawi: Secondary Analysis from the MORDOR Trial.

Authors:  John D Hart; Khumbo Kalua; Jeremy D Keenan; Thomas M Lietman; Robin L Bailey
Journal:  Am J Trop Med Hyg       Date:  2020-09       Impact factor: 2.345

4.  Effects of Biannual Azithromycin Mass Drug Administration on Malaria in Malawian Children: A Cluster-Randomized Trial.

Authors:  John D Hart; Lyson Samikwa; Feston Sikina; Khumbo Kalua; Jeremy D Keenan; Thomas M Lietman; Sarah E Burr; Robin L Bailey
Journal:  Am J Trop Med Hyg       Date:  2020-09       Impact factor: 2.345

5.  Prevalence of nasopharyngeal Streptococcus pneumoniae carriage and resistance to macrolides in the setting of azithromycin mass drug administration: analysis from a cluster-randomised controlled trial in Malawi, 2015-17.

Authors:  John D Hart; Lyson Samikwa; Harry Meleke; Sarah E Burr; Jen Cornick; Khumbo Kalua; Robin L Bailey
Journal:  Lancet Microbe       Date:  2022-02

6.  Mass Azithromycin and Malaria Parasitemia in Niger: Results from a Community-Randomized Trial.

Authors:  Kieran S O'Brien; Sun Y Cotter; Abdou Amza; Boubacar Kadri; Baido Nassirou; Nicole E Stoller; Zhaoxia Zhou; Chris Cotter; Sheila K West; Robin L Bailey; Philip J Rosenthal; Bruce D Gaynor; Travis C Porco; Thomas M Lietman
Journal:  Am J Trop Med Hyg       Date:  2017-07-19       Impact factor: 2.345

7.  Malaria Parasitemia and Nutritional Status during the Low Transmission Season in the Presence of Azithromycin Distribution among Preschool Children in Niger.

Authors:  Ahmed M Arzika; Ramatou Maliki; Nameywa Boubacar; Salissou Kane; Catherine A Cook; Elodie Lebas; Ying Lin; Kieran S O'Brien; Ariana Austin; Jeremy D Keenan; Thomas M Lietman; Catherine E Oldenburg
Journal:  Am J Trop Med Hyg       Date:  2020-09       Impact factor: 2.345

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.